Updated Abraxane Monograph in DrugDex
On February 4, 2009 DrugDex updated its Abraxane monograph to include first-line combination treatment of NSCLC. The language from the DrugDex monograph appears below.
4.5.E Non-small cell lung cancer, Advanced or metastatic, first-line treatment, in combination with carboplatin and bevacizumab
1) Overview
FDA Approval: Adult, no; Pediatric, no
Efficacy: Adult, Evidence favors efficacy
Recommendation: Adult, Class IIb
Strength of Evidence: Adult, Category B
See Drug Consult reference: RECOMMENDATION AND EVIDENCE RATINGS
2) Summary:
In an open-label, phase 2 study presented in abstract form and as a presentation (n=50), 31.3% of patients with advanced non-small-cell lung cancer (NSCLC) achieved a partial response following first-line therapy with nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab.(Reynolds et al, 2007; Reynoldset al,null).
Copies of the updated Abraxane monograph are available at Abraxis Oncology’s ARC of Support – that number is (800) 564-0216, Option 3. Representatives are available from 8 AM to 8 PM, Monday to Friday.
Novartis Announces Afinitor® Approved for Advanced Renal Cell Carcinoma
Novartis Pharmaceuticals Corporation is pleased to announce the introduction of Afinitor® (everolimus) tablets, approved by the FDA on March 30, 2009. Afinitor® is a once daily oral mTOR inhibitor indicated for the treatment of advanced Renal Cell Carcinoma (RCC). Afinitor® is available by prescription only and package in a blister card.
More information:
Click Here for the Letter to Wholesalers
Click Here for Pharmacy Ordering Instructions
Click Here for the Labeling Revised 03/2009
| 
